HHC Medical is developing a platform technology for targeted, non-invasive drug delivery using wireless electroporation, which enhances the precision of drug administration while minimizing side effects. This approach addresses the limitations of traditional drug delivery methods by improving safety and allowing for diverse therapeutic payloads.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug delivery methods often lack precision, leading to systemic exposure and potential side effects. This limits the therapeutic window and restricts the use of certain drugs that are too toxic for widespread distribution. Current approaches also struggle to effectively target specific tissues or cells, hindering treatment efficacy.
Solution
HHC Medical is developing a platform for targeted, non-invasive drug delivery using wireless electroporation. This technology enhances drug administration precision, minimizing off-target effects and improving overall safety. Wireless electroporation temporarily disrupts the cell membrane, allowing for enhanced drug uptake directly at the targeted site. The platform aims to enable the delivery of diverse therapeutic payloads, expanding treatment options for various diseases. By focusing the drug's effect locally, HHC Medical's approach seeks to improve patient outcomes and reduce the burden of systemic toxicity.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and healthcare providers seeking more precise and safer drug delivery methods.
Features
- Wireless electroporation technology for non-invasive drug delivery
- Targeted drug administration to specific tissues or cells
- Enhanced drug uptake through temporary cell membrane disruption
- Platform compatible with diverse therapeutic payloads
- Improved safety profile compared to traditional methods